select a format

Single User License
USD 250 INR 16255
Site License
USD 500 INR 32510
Corporate User License
USD 750 INR 48765

Alternatively

Request a quote
Request a Customized research
Request for Sample Report

NEWSLETTER BY CATEGORY




Recent Viewed Reports


Why Ken Reasearch?


Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"


Zogenix Inc (ZGNX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Zogenix Inc (ZGNX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH17626D
  • |
  • Pages: 57
  • |
  • May 2017
  • |
  • |
  Request for Sample Report

Executive Summary

Summary

Zogenix Inc (Zogenix) is a pharmaceutical company that develops and commercializes injectable therapies and delivery systems for treating central nervous system disorders and pain. The company's product portfolio includes Zohydro ER, Sumavel DosePro and undisclosed dosepro CNS product candidate. Its pipeline products include Relday and ZX008. Zogenix's Sumavel DosePro is a prefilled needle-free delivery system that treats people with acute migraine or cluster headaches. The company partners with Battelle to offer DosePro technology to its pharmaceutical partners. It also provides education materials on therapeutic products for patients and physicians. Zogenix is headquartered in Emeryville, California, the US.

Zogenix Inc (ZGNX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Zogenix Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Zogenix Inc, Medical Devices Deals, 2011 to YTD 2017 10

Zogenix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Zogenix Inc, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Zogenix And Battelle Memorial Institute Extend Co-Marketing Agreement For DosePro 12

Zogenix Enters Into Co-Promotion Agreement With Valeant Pharma For Migranal Nasal Spray 13

Zogenix And Battelle Memorial Institute Extend Co-Marketing Agreement For DosePro 14

Zogenix Enters Into Co-Promotion Agreement With Mallinckrodt For Sumavel DosePro 15

Zogenix Enters Into Co-Marketing Agreement With Battelle Memorial Institute For DosePro 16

Licensing Agreements 17

Zogenix Amends Licensing Agreement with Daravita 17

Zogenix Enters Into Licensing Agreement With Altus Formulation For Zohydro ER 18

Zogenix Amends Agreement with Elan Pharma 19

Zogenix Enters Into Licensing Agreement With DURECT 20

Equity Offering 21

Zogenix Raises USD98.3 Million in Public Offering of Shares 21

Zogenix Completes Public Offering Of Shares For US$69 Million 22

Zogenix Announces Public Offering Of Shares For Up To US$25 Million 24

Zogenix Completes Public Offering Of Units For US$70 Million 25

Zogenix Completes Public Offering Of Common Stock For US$61.4 Million 26

Zogenix Completes Private Placement Of Common Stock For US$1.5 Million 27

Asset Transactions 28

Pernix Acquires Zohydro ER Business from Zogenix 28

Endo International Completes Acquisition of Sumavel DosePro Migraine Therapy Business from Zogenix 30

Cowen Healthcare Royalty Partners Acquires Royalties Of SUMAVEL DosePro And Zohydro From Zogenix 31

Acquisition 32

Zogenix Acquires Brabant Pharma for USD130 Million 32

Zogenix Inc-Key Competitors 34

Key Employees 35

Locations And Subsidiaries 36

Head Office 36

Other Locations & Subsidiaries 36

Recent Developments 37

Financial Announcements 37

May 04, 2017: Zogenix Reports First Quarter 2017 Financial Results 37

Mar 09, 2017: Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2016 Financial Results 38

Nov 08, 2016: Zogenix Provides Corporate Update and Reports Third Quarter 2016 Financial Results 40

Aug 09, 2016: Zogenix Provides Corporate Update and Reports Second Quarter 2016 Financial Results 42

May 10, 2016: Zogenix Provides Corporate Update and Reports First Quarter 2016 Financial Results 43

Mar 10, 2016: Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2015 Financial Results 44

Corporate Communications 46

Jan 05, 2017: Zogenix Announces CFO Transition 46

Product News 47

04/21/2016: New Data on Zogenix ZX008 for Dravet Syndrome to be Presented at 14th International Child Neurology Congress 47

Product Approvals 48

Mar 01, 2017: Zogenix Receives Orphan Drug Designation in the European Union for ZX008 in Lennox Gastaut Syndrome 48

Jan 19, 2016: Zogenix Receives Fast Track Designation From FDA for Development of ZX008 in Dravet Syndrome 49

Clinical Trials 50

Feb 13, 2017: Zogenix Announces Initiation of Clinical Efficacy Portion of Study 1504 for ZX008 in Dravet Syndrome 50

Dec 05, 2016: Zogenix Announces New Efficacy and Safety Data for ZX008 in Treatment of Seizures in Lennox Gastaut Syndrome & Dravet Syndrome 51

Nov 22, 2016: New Data on Zogenixs ZX008 for Lennox Gastaut Syndrome & Dravet Syndrome to be Presented at 70th Annual American Epilepsy Society Meeting 53

Jun 07, 2016: Zogenix Announces Initiation of Multi-National Phase 3 Clinical Trial for ZX008 in Dravet Syndrome 54

May 05, 2016: Zogenix Announces ZX008 New Efficacy and Safety Data for Treatment of Seizures in Dravet Syndrome 55

Jan 11, 2016: Zogenix Announces Initiation of Phase 3 Program for ZX008 in Dravet Syndrome 56

Appendix 57

Methodology 57

About GlobalData 57

Contact Us 57

Disclaimer 57

List of Figures

Zogenix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Zogenix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Zogenix Inc, Medical Devices Deals, 2011 to YTD 2017 10

List of Tables

Zogenix Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 1

Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Zogenix Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Zogenix Inc, Deals By Therapy Area, 2011 to YTD 2017 9

Zogenix Inc, Medical Devices Deals, 2011 to YTD 2017 10

Zogenix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Zogenix And Battelle Memorial Institute Extend Co-Marketing Agreement For DosePro 12

Zogenix Enters Into Co-Promotion Agreement With Valeant Pharma For Migranal Nasal Spray 13

Zogenix And Battelle Memorial Institute Extend Co-Marketing Agreement For DosePro 14

Zogenix Enters Into Co-Promotion Agreement With Mallinckrodt For Sumavel DosePro 15

Zogenix Enters Into Co-Marketing Agreement With Battelle Memorial Institute For DosePro 16

Zogenix Amends Licensing Agreement with Daravita 17

Zogenix Enters Into Licensing Agreement With Altus Formulation For Zohydro ER 18

Zogenix Amends Agreement with Elan Pharma 19

Zogenix Enters Into Licensing Agreement With DURECT 20

Zogenix Raises USD98.3 Million in Public Offering of Shares 21

Zogenix Completes Public Offering Of Shares For US$69 Million 22

Zogenix Announces Public Offering Of Shares For Up To US$25 Million 24

Zogenix Completes Public Offering Of Units For US$70 Million 25

Zogenix Completes Public Offering Of Common Stock For US$61.4 Million 26

Zogenix Completes Private Placement Of Common Stock For US$1.5 Million 27

Pernix Acquires Zohydro ER Business from Zogenix 28

Endo International Completes Acquisition of Sumavel DosePro Migraine Therapy Business from Zogenix 30

Cowen Healthcare Royalty Partners Acquires Royalties Of SUMAVEL DosePro And Zohydro From Zogenix 31

Zogenix Acquires Brabant Pharma for USD130 Million 32

Zogenix Inc, Key Competitors 34

Zogenix Inc, Key Employees 35

Zogenix Inc, Other Locations 36

Zogenix Inc, Subsidiaries 36

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Zogenix Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com